Detect bladder cancer recurrence
up to 6 months sooner than other diagnostic methods

Earlier detection is the key to increased survival

Vysis UroVysion’s™ molecular cytology combines the strength of urine cytology (morphology) with molecular (DNA-based) technology to enhance the detection of the presence of cancer

- Offers greater sensitivity than tests such as cytology or biomarkers, which translates into fewer false negatives
- Earlier detection allows you to treat your patient’s cancer more aggressively as needed
- Detects high grade pT1 and pTis tumors that can be overlooked with traditional diagnostic methods and have high progression rates to muscle-invasive cancer
- Provides results you can count on – Vysis UroVysion™ is the first FDA-approved genomic DNA-probe test for identifying early recurrence of bladder cancer
- Not affected by BCG Immunotherapy

With Vysis UroVysion™ you now have a superior option to accurately manage bladder cancer recurrence
Sensitivity
Vysis UroVysion™ is not only more sensitive than urine cytology by stage, but also more sensitive by grade.

![Sensitivity (%) by Stage](image_url)

**Specificity**
The specificity of Vysis UroVysion™ is approximately 95% among healthy and non-healthy subjects, which translates to fewer false positives.

![Vysis UroVysion™ Images](image_url)

**Accuracy and sensitivity make Vysis UroVysion™ the best method for detecting bladder cancer recurrence**

For more information on Vysis UroVysion™ contact your Quest Diagnostics sales representative or visit us at [www.questdiagnostics.com](http://www.questdiagnostics.com).

References
1. The source of this claim is the Vysis UroVysion™ Package Insert.